Biomarkers for Prostate Biopsy and Risk Stratification of Patients with Newly Diagnosed Prostate Cancer

References

• 1 International Agency for Research on Cancer: GLOBOCAN 2012 Prostate Cancer Fact Sheet. Available at http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed September 20, 2015. Google Scholar
• 2 American Cancer Society: Cancer Facts and Figures 2016. Available at http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed May 5, 2016. Google Scholar
• 3 : Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet2014; 384: 2027. Google Scholar
• 4 : Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst2012; 104: 125. Google Scholar
• 5 : Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med2004; 350: 2239. Google Scholar
• 6 : Complications after prostate biopsy: data from SEER-Medicare. J Urol2011; 186: 1830. Link, Google Scholar
• 7 : Reducing the harm of prostate cancer screening: repeated prostate-specific antigen testing. Mayo Clin Proc2016; 91: 17. Google Scholar
• 8 : Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol2008; 180: 1959. Link, Google Scholar
• 9 : Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA1993; 270: 860. Google Scholar
• 10 American Urological Association: Early Detection of Prostate Cancer: AUA Guideline. Available at http://www.auanet.org/education/guidelines/prostate-cancer-detection.cfm. Accessed May 12, 2013. Google Scholar
• 11 : Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med2012; 367: 203. Google Scholar
• 12 : Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA1992; 267: 2215. Google Scholar
• 13 : Saw palmetto for benign prostatic hyperplasia. N Engl J Med2006; 354: 557. Google Scholar
• 14 : Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?. BJU Int2008; 101: 817. Google Scholar
• 15 : Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med2004; 351: 125. Google Scholar
• 16 : Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology2008; 71: 1016. Google Scholar
• 17 : Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol2009; 27: 398. Google Scholar
• 18 : Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology2007; 70: 685. Google Scholar
• 19 : Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int2012; 109: 508. Google Scholar
• 20 : Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol1992; 147: 815. Link, Google Scholar
• 21 : Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol2012; 61: 577. Google Scholar
• 22 : Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem1991; 37: 1618. Google Scholar
• 23 National Comprehensive Cancer Network Guidelines: Prostate Cancer Early Detection 2016. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed March 14, 2016. Google Scholar
• 24 : Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology1998; 51: 558. Google Scholar
• 25 : A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol2011; 185: 1650. Link, Google Scholar
• 26 : The Prostate Health Index: its utility in prostate cancer detection. Urol Clin North Am2016; 43: 1. Google Scholar
• 27 : The Prostate Health Index selectively identifies clinically significant prostate cancer. J Urol2015; 193: 1163. Link, Google Scholar
• 28 : Multicenter evaluation of the Prostate Health Index to detect aggressive prostate cancer in biopsy naïve men. J Urol2015; 194: 65. Link, Google Scholar
• 29 : Multicenter European external validation of a Prostate Health Index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol2014; 66: 906. Google Scholar
• 30 : Comparison of two prostate cancer risk calculators that include the Prostate Health Index. Eur Urol Focus2015; 1: 185. Google Scholar
• 31 Roobol M, Salman J and Azevedo N: The Rotterdam prostate cancer risk calculator: improved prediction with more relevant pre-biopsy information, now in the palm of your hand. Presented at the Annual European Association of Urology Congress, Stockholm, Sweden, April 11-15, 2014. Google Scholar
• 32 : A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med2008; 6: 19. Google Scholar
• 33 : A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev2011; 20: 255. Google Scholar
• 34 : A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol2015; 68: 464. Google Scholar
• 35 : Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer. Eur Urol2015; 68: 139. Google Scholar
• 36 : DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res1999; 59: 5975. Google Scholar
• 37 : DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res2002; 62: 2695. Google Scholar
• 38 : DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol2003; 44: 8. Google Scholar
• 39 : PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology2007; 69: 532. Google Scholar
• 40 : Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol2008; 54: 1081. Google Scholar
• 41 : External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol2010; 58: 727. Google Scholar
• 42 : Accuracy of the Prostate Health Index versus the urinary Prostate Cancer Antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate2015; 75: 103. Google Scholar
• 43 : Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol2013; 189: 1110. Link, Google Scholar
• 44 : Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol2014; 192: 1081. Link, Google Scholar
• 45 : Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol2015; 68: 1045. Google Scholar
• 46 : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA1998; 280: 969. Google Scholar
• 47 : The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol1993; 150: 110. Abstract, Google Scholar
• 48 : A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst1998; 90: 766. Google Scholar
• 49 : The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol2005; 173: 1938. Link, Google Scholar
• 50 : Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol2012; 188: 1131. Link, Google Scholar
• 51 : The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol2014; 140: 257. Google Scholar
• 52 : Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric European prospective study. Eur Urol2015; 68: 132. Google Scholar
• 53 : PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol2016; 34: 485. Google Scholar
• 54 : Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: results from a prospective single-center study. Urol Oncol2015; 33: 337. Google Scholar
• 55 : Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur Urol2013; 64: 693. Google Scholar
• 56 : Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur Urol2015; 68: 207. Google Scholar
• 57 : PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol2008; 179: 1804. Link, Google Scholar
• 58 : Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol2011; 59: 96. Google Scholar
• 59 : Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol2011; 60: 1045. Google Scholar
• 60 : Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol2010; 183: 534. Link, Google Scholar
• 61 : Genomic predictors of outcome in prostate cancer. Eur Urol2015; 68: 1033. Google Scholar
• 62 : Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer2012; 106: 1095. Google Scholar
• 63 : A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol2014; 66: 550. Google Scholar
• 64 : Application of a clinical whole-transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens. J Mol Diagn2016; 18: 395. Google Scholar
• 65 National Institute for Health and Care Excellence: Protocol for Active Surveillance. Available at http://pathways.nice.org.uk. Accessed December 1, 2015. Google Scholar
• 66 : Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol2015; 67: 627. Google Scholar